Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Relugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their Offspring

NCT05739123 is registered in ClinicalTrials.gov with Sumitomo Pharma Switzerland GmbH as lead sponsor.

NCT NCT05739123
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05739123 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Relugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their Offspring
Lead sponsor
Sumitomo Pharma Switzerland GmbH
Phase
Observational
Overall status
Recruiting
Start date
May 8, 2023
Completion date
May 31, 2033
Enrollment
728 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pregnancy complications, pregnancy related, pregnancy, high risk